Eurobio Scientific Business Model Canvas

Universities, reference labs and hospital consortia enable biomarker discovery and clinical studies, supplying samples and real-world data for validation; IVDR (EU) 2017/746, in application since 26 May 2022, mandates such clinical evidence. Access to samples supports analytical and clinical validation and IVDR evidence generation. KOLs shape study protocols and drive clinical adoption, while peer-reviewed publications strengthen credibility and reimbursement dossiers.

OEM co-development and assay partnerships expand the test menu and access to the global IVD market (~USD 88B in 2024). Strategic multi-sourcing of reagents stabilizes cost within the ~USD 30B reagents market (2023) and reduces supply risk. Academic, hospital and regulatory partners generate IVDR-compliant clinical evidence (IVDR applicable 26 May 2022). Regional distributors and cold-chain partners reach >60 countries (2024).

Compilation of technical documentation and performance evaluation under IVDR (in force since 26 May 2022) to maintain CE-IVD compliance. Market surveillance, complaint handling and CAPA processes follow IVDR vigilance timelines, including serious-incident reporting within 15 days. UDI, labeling and PMS reporting are maintained continuously, with proactive liaison with notified bodies and competent authorities to secure market access.

R&D focuses on PCR, immunoassay and molecular assays optimized for sensitivity, automation and IVDR-aligned validation (IVDR in force since 26 May 2022). ISO 13485 production ensures lot release, stability and GS1 traceability; supply chain enforces S&OP, cold-chain and dual sourcing. Commercial channels combine direct hospital sales, distributor enablement, application support and tender/key account management.

Regulatory & QA teams comprise experienced RA/QA professionals managing submissions and audits, aligned with ISO 13485 and MDR updates through 2024. Vigilance and PMS analysts monitor field performance and maintain post-market surveillance databases to detect trends and signal events. Documentation specialists ensure full traceability of device histories and batch records, supporting audit readiness. Cross-functional training programs sustain a compliance culture across R&D, manufacturing and commercial functions.

Core assets include patented assays, validated lyophilization and traceable QA systems (ISO 13485; ISO/IEC 17025) with IVDR alignment by 2024, certified cleanrooms (ISO 7/8) and automated filling lines. Commercial reach spans 30+ countries supported by CRM, KOLs in infectious disease/oncology/transplantation and cold-chain logistics. Cross-functional RA/QA teams and contract manufacturers ensure surge capacity and audit readiness.

CE-IVD and IVDR-aligned assays deliver strong clinical evidence and conformity with IVDR, fully applicable since May 26, 2022, reducing market access risk. Comprehensive, transparent documentation streamlines audits and tender submissions. Active post-market vigilance meets IVDR vigilance requirements, enhancing continuous safety. This lowers regulatory burden on laboratories through validated, audit-ready solutions.

Clinically validated, IVDR-aligned assays across infectious disease, transplantation and oncology enable fast, audit-ready results and streamlined workflows; 2024 assay panel updates broaden coverage and cross-platform compatibility. Hybrid proprietary+third-party model reduces validation time and accelerates lab adoption; local training and remote support minimise downtime.

Application support provides hands-on method setup, validation assistance, and rapid troubleshooting to ensure assay performance and regulatory readiness. Workflow optimization services align protocols and instrument capacity to customer throughput goals and reduce time-to-result. Sample-to-answer training materials and continuous guidance for new assays deliver repeatable competence across lab teams.

Dedicated KAMs manage 1–5yr contracts with volume discounts up to 25% and SLAs targeting 99.5% uptime; typical annual service fee ~10% of equipment value. Application support, SOP harmonization and training reduce TTR and variability across multi-site networks. Co-development with labs/biopharma yields custom kits and joint validations; Eurobio Scientific listed on Euronext Paris (2024).

Eurobio Scientifics e-commerce portal offers an online catalog for reagents and consumables with ordering, shipment tracking and lot documentation access, enabling compliance and traceability. It includes self-service technical resources (protocols, FAQs, SDS) and API-based integration with procurement systems for PO automation. Eurobio Scientific is listed on Euronext Paris, supporting digital sales expansion.

In-country teams with on-site demos and 3–5 year framework contracts drove instrument and reagent adoption in 2024. Authorized resellers in 25+ markets trained 1,200+ technicians and supplied ~15% of new leads. E‑commerce, GPOs (10–20% savings) and congresses (ECCMID 12k; ASCO 40k) broadened reach.

Transplant centers monitor graft rejection and infection risk using specialized assays that demand tight QC and ISO 15189-accredited lab workflows. Traceability and robust clinical evidence are mandated under IVDR 2017/746 and FDA guidance, driving adoption of CE-IVD/FDA-cleared tests. Complex workflows require dedicated training programs, often on-site or 1–3 day certified sessions to ensure operator competency.

Hospitals/clinics need high‑throughput, ISO15189‑grade IVDs; global IVD market ≈ $90B (2023). Reference labs seek low cost‑per‑test and 24–48h TAT; scalable platforms required. Research, biotech and transplant centers demand flexible assays, CE‑IVD/FDA evidence; reagents/consumables market >$65B (2024); public health needs surge capacity (EU4Health €5.1B).

Notified body fees, audits and documentation drive recurring certification costs, with industry 2024 surveys showing medtech firms allocating roughly 6% of revenue to regulatory and quality activities. PMS, vigilance and CAPA generate ongoing operational spend and recall risk mitigation budgets. Labeling, UDI rollout and compliance IT require capital and maintenance investment, while training and internal audits sustain compliance and traceability.

Eurobio Scientific 2024 cost structure: R&D and clinical validation drove multi‑million euro spend with instrument/software and sustaining engineering as significant capital lines. Reagents and single‑use items represent ~45% of manufacturing COGS; facility overhead ~12% and equipment depreciation ~8% of manufacture costs. Regulatory/quality ~6% of revenue; distributor margins 20–35% and CRM/tender admin 8–12% of S&M.

Service contracts covering maintenance, calibration and extended warranties create predictable, sticky revenues for Eurobio Scientific by converting one‑time device sales into ongoing cashflows. Tiered SLAs and managed service offerings support upsell and higher-margin support tiers, improving customer retention and lifecycle value. Industry benchmarks in 2024 show recurring service revenue often represents roughly 25–35% of total platform-related revenues, strengthening balance‑sheet resilience.

Reagents/consumables: recurring high-margin sales; core driver in 2024, double-digit organic growth.

Instruments: upfront sales + placement models to seed consumables; bundled pricing and trade-ins boost uptake.

Services & distribution: services ≈25–35% of platform revenues; distribution helped reach €243.7m revenue in 2024.